HeartBeam receives FDA breakthrough status for heart attack assessment
The designation offers prioritized FDA interaction, while a pivotal study and separate clearance submission still lie ahead.
Adrian Kessler
Prioritized FDA interaction is available to HeartBeam, Inc. NASDAQBEAT after the agency granted Breakthrough Device designation to its ECG system for assessing possible heart attacks at home, the company said Monday. A 134-patient pilot helped support the designation, but HeartBeam plans a pivotal study before seeking clearance for the new use.
The FDA's program offers developers opportunities to interact with agency experts and prioritized review of a later marketing submission; designation does not authorize the heart attack use. HeartBeam says it will seek FDA agreement on a multicentre pivotal study, then use a successful trial to support an application to expand the system's indications. The company said the FDA granted the designation within 30 days of its request, ahead of what it called the agency's 60-day statutory review period.
HeartBeam, based in Santa Clara, develops a portable electrocardiogram platform for cardiac assessment outside hospitals and clinics.
The NASDAQBEAT page showed HeartBeam shares at US$0.43 at about 4 p.m. EDT at the Friday, Oct. 2, Nasdaq close. That price predates Monday's announcement, so it cannot show a reaction to the designation.
Pilot Data Must Still Shape the Trial
The system collects signals from three directions and synthesizes a 12-lead ECG. Its existing clearance covers arrhythmia assessment, while Monday's designation concerns the proposed use for assessing possible heart attacks at home. HeartBeam still needs a separate clinical and regulatory case for the new indication.
HeartBeam said the designation drew on proof-of-concept work presented in 2025 and the ALIGN-ACS pilot. Its Oct. 5 release provides no sensitivity or specificity figures for heart attack assessment, and the pivotal protocol still needs FDA agreement. The company expects the multicentre study, if successful, to support a future submission.
"While hospital systems have significantly improved time to treatment inside medical facilities, patients often still delay seeking care because symptoms can be subtle or easily dismissed," Tony Das, a member of HeartBeam's scientific advisory board, said in the Oct. 5 release.
The FDA's Aug. 31 program page limits eligibility to devices that provide for more effective diagnosis or treatment of life-threatening or irreversibly debilitating diseases or conditions. Eligible devices must also meet another criterion, such as offering a significant advantage over approved or cleared alternatives. Designated devices still face the agency's safety and effectiveness standards before marketing.
HeartBeam also sees a possible reimbursement route. Its release says breakthrough status is a prerequisite for certain expedited Medicare pathways and describes the joint FDA-CMS RAPID pathway as a proposal. Neither the designation nor that proposal is a Medicare coverage decision for HeartBeam's heart attack use.
Device Peers Have Separate Regulatory Milestones
Cardiovascular device peers include Medtronic plc NYSEMDT, whose corporate site describes its medical technology portfolio, and Edwards Lifesciences Corporation NYSEEW, whose corporate site describes its heart device business. HeartBeam's Oct. 5 release places its proposed heart attack use at the pivotal study design stage.
Read more: Medtronic reports 88.1 per cent ulcer healing in two-year VenaSeal study
Read more: Edwards Lifesciences gains FDA approval for expandable pediatric valve
The TCT conference runs from Oct. 31 to Nov. 3, and HeartBeam's Oct. 5 release identifies an ALIGN-ACS data presentation at the meeting. The company separately expects an update on HEADSTART-ACS but gives no date for it. The presentation will show pilot evidence ahead of a pivotal design discussion with the FDA; HeartBeam's Oct. 5 release gives no date for a clearance filing.
